Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijo Bilusic

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Expert Review of Anticancer Therapy|April 27, 2022
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?Marijo Bilusic
Current Oncology Reports|March 18, 2017
Current Management Strategy for Metastatic Renal Cell Carcinoma and Future DirectionsHussein Merza, Marijo Bilusic
Cancer Management and Research|September 5, 2020
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to DateVincent Chau, Marijo Bilusic
Expert Review of Anticancer Therapy|March 3, 2025
Overcoming common emerging barriers to effective neoadjuvant immunotherapiesSophia Sokol, Marijo Bilusic
Cancer Immunology, Immunotherapy : CII|November 29, 2011
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesMarijo Bilusic, James L Gulley
Hematology/Oncology Clinics of North America|March 6, 2019
Cancer VaccinesPeter J DeMaria, Marijo Bilusic
Journal of the National Cancer Institute|July 28, 2018
Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot"Marijo Bilusic, James L Gulley
American Journal of Therapeutics|February 15, 2011
Therapeutic cancer vaccines: the latest advancement in targeted therapyMarijo Bilusic, Ravi A Madan
Asian Journal of Andrology|April 25, 2014
Anti-angiogenesis in prostate cancer: knocked down but not outMarijo Bilusic, Yu-Ning Wong
Asian Journal of Andrology|December 15, 2010
Cabazitaxel: a new drug for metastatic prostate cancerMarijo Bilusic, William L Dahut
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Expert Review of Anticancer Therapy|April 27, 2022
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?Marijo Bilusic
Current Oncology Reports|March 18, 2017
Current Management Strategy for Metastatic Renal Cell Carcinoma and Future DirectionsHussein Merza, Marijo Bilusic
Cancer Management and Research|September 5, 2020
Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to DateVincent Chau, Marijo Bilusic
Expert Review of Anticancer Therapy|March 3, 2025
Overcoming common emerging barriers to effective neoadjuvant immunotherapiesSophia Sokol, Marijo Bilusic
Cancer Immunology, Immunotherapy : CII|November 29, 2011
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesMarijo Bilusic, James L Gulley
Hematology/Oncology Clinics of North America|March 6, 2019
Cancer VaccinesPeter J DeMaria, Marijo Bilusic
Journal of the National Cancer Institute|July 28, 2018
Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot"Marijo Bilusic, James L Gulley
American Journal of Therapeutics|February 15, 2011
Therapeutic cancer vaccines: the latest advancement in targeted therapyMarijo Bilusic, Ravi A Madan
Asian Journal of Andrology|April 25, 2014
Anti-angiogenesis in prostate cancer: knocked down but not outMarijo Bilusic, Yu-Ning Wong
Asian Journal of Andrology|December 15, 2010
Cabazitaxel: a new drug for metastatic prostate cancerMarijo Bilusic, William L Dahut
Pageof 8